Genglycos becomes first FDA-approved GSDIa therapy as Ultragenyx turns AAV8 gene therapy into a commercial product
FDA accelerated approval makes Genglycos the first treatment for GSDIa, based on a 31% reduction in daily cornstarch intake that must now be confirmed through long-term follow-up.